Allspring Global Investments Holdings LLC increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) by 289.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,646 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,170 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Supernus Pharmaceuticals were worth $326,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. First Horizon Advisors Inc. bought a new position in Supernus Pharmaceuticals during the second quarter worth about $34,000. Eagle Bay Advisors LLC raised its holdings in Supernus Pharmaceuticals by 143.0% during the 2nd quarter. Eagle Bay Advisors LLC now owns 2,663 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 1,567 shares during the last quarter. Captrust Financial Advisors grew its position in Supernus Pharmaceuticals by 163.3% during the first quarter. Captrust Financial Advisors now owns 2,983 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 1,850 shares during the period. Nisa Investment Advisors LLC grew its position in Supernus Pharmaceuticals by 28.4% during the second quarter. Nisa Investment Advisors LLC now owns 3,390 shares of the specialty pharmaceutical company’s stock valued at $98,000 after buying an additional 750 shares during the period. Finally, Lazard Asset Management LLC grew its position in Supernus Pharmaceuticals by 71.6% during the second quarter. Lazard Asset Management LLC now owns 3,498 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,460 shares during the period. 99.82% of the stock is owned by institutional investors.
Insider Buying and Selling at Supernus Pharmaceuticals
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 6,800 shares of the business’s stock in a transaction dated Friday, November 11th. The stock was sold at an average price of $34.95, for a total transaction of $237,660.00. Following the completion of the sale, the vice president now directly owns 1,644 shares in the company, valued at approximately $57,457.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $37.48, for a total transaction of $187,400.00. Following the sale, the vice president now directly owns 1,644 shares of the company’s stock, valued at approximately $61,617.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 6,800 shares of the stock in a transaction on Friday, November 11th. The shares were sold at an average price of $34.95, for a total value of $237,660.00. Following the sale, the vice president now owns 1,644 shares in the company, valued at approximately $57,457.80. The disclosure for this sale can be found here. Insiders sold a total of 69,340 shares of company stock worth $2,629,303 in the last three months. 8.70% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Supernus Pharmaceuticals Stock Performance
Shares of NASDAQ:SUPN opened at $41.41 on Wednesday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $24.95 and a fifty-two week high of $41.69. The business has a 50-day simple moving average of $37.04 and a two-hundred day simple moving average of $34.49. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 64.70 and a beta of 0.94.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.29). Supernus Pharmaceuticals had a return on equity of 4.51% and a net margin of 5.72%. The business had revenue of $177.35 million during the quarter, compared to analysts’ expectations of $173.22 million. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.63 earnings per share for the current year.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.